Capricor Therapeutics Faces Potential Lawsuit Over Investor Losses
Capricor Therapeutics shareholders are encouraged to contact legal counsel regarding potential lead roles in a securities lawsuit. The action concerns share purchases made during a specified period.
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is facing potential legal scrutiny following a notice issued by The Gross Law Firm to its shareholders. The firm is seeking shareholders who purchased CAPR shares during a specific class period to contact them regarding potential lead plaintiff roles in a securities lawsuit.
The lawsuit focuses on allegations related to Capricor Therapeutics' securities. Investors who incurred losses on the value of their shares within the mentioned period are urged to reach out to The Gross Law Firm to gather information and assess their opportunities to participate in the legal proceedings.
Further details regarding the class period and the grounds for the lawsuit are available through the law firm. Shareholders are advised to contact the firm to discuss their legal options.